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Objective. We aimed at assessing the basic coagulation parameters of HIV-infected adults at the University of Gondar Hospital
antiretroviral therapy clinic. Methods. A comparative cross-sectional study was conducted from February to May 2017. A total of
300 study participants, consisting of 100 HAART-na¨ıve HIV-infected adults, 100HIV-infected adults who were taking HAART,
and 100HIV-seronegative apparently healthy adults, were included. Basic coagulation functional assays such as PT, APTT, and
INR were determined by coagulation analyzer. CD4 cells and platelet count were analyzed by FACS count and SYSMEX K-21N
automated analyzer, respectively. The data were entered, cleaned, and edited using Epi Info version 7 and analyzed using SPSS
version 20. Kruskal-Wallis H, Dunn-Bonferroni pairwise comparison test, and Spearman’s rank-order correlation analysis were
used for inferential statistics. The results were expressed by a median and presented in tables. 𝑃 value < 0.05 was considered as
statistically significant. Results. PT, APTT, and INRwere significantly higher, whereas platelet count was significantly lower in HIV-
infected adults (both who were taking HAART and HAART-naı¨ve) than HIV-seronegative adults (𝑃 < 0.001). PT and INR were
significantly higher, and platelet count was significantly lower in HAART-naı¨ve HIV-infected adults than HIV-infected adults who
were taking HAART. In Spearman’s rank-order correlation analysis, APTT has shown a significant negative correlation with a CD4
count in HAART-na¨ıve HIV-infected adults. Conclusion. HIV-infected adults are more likely to develop coagulation abnormality
than HIV-seronegative subjects. Coagulation parameters need to be checked regularly to monitor coagulation disorders in HIV-
infected adults.
1. Introduction
Human immunodeficiency virus causes acquired immun-
odeficiency syndrome and causes significant morbidity and
mortality by various mechanisms and one among them is
hemostatic abnormalities [1, 2]. HIV continues to be a major
global public health issue. As to World Health Organization
(WHO) report of 2016, more than 35 million are living with
HIV, of which about three-fourth are living in WHOAfrican
Region. Moreover, 1.0 and 1.8 million people died from
HIV-related causes and became newly infected globally in
2016, respectively [3].
Hemostasis is a system that consists of different cellular
and biochemical events that play a main role in keeping
the blood in a liquid state within circulation, to prevent
the occurrences of thrombotic and bleeding complication
[4]. Different systems are working together to maintain the
balance between excessive bleeding and thrombosis includ-
ing a vascular system, coagulation system, fibrinolytic sys-
tem, platelets, and protease inhibitors. Those systems work
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together to prevent bleeding and clotting problem [5]. In nor-
mal healthy individuals, the hemostatic system is in a delicate
balance between excessive bleeding state and clotting. How-
ever, abnormalities in the system cause either hemorrhagic or
clotting disorder [6].
There are different factors that affect the normal hemo-
static system, of which HIV infection is known to have been
one of the main causes of hemostatic abnormality [7]. HIV
infection causes serious haemostatic complication especially
in the late stage ofHIV infection, as immune suppression, and
the presence of concurrent infection or neoplastic diseases
exacerbates the condition [8]. It is the major causes of the
haematological disorder, as the virus deregulates haemato-
poiesis process and the coagulation system. The virus itself,
virus-associated opportunistic infections, adverse effect of
antiretroviral therapies (ART), and other associated compli-
cations were the possible cause of the abnormalities [9–11].
Coagulation abnormalities in HIV patients can be attrib-
uted from the effect of the virus which can cause a number of
abnormalities that predispose the patients to the occurrences
of coagulation disorder. The abnormalities caused by HIV
infection include thrombocytopenia [11], endothelial cell
dysfunction, activation of coagulation factors, and presence
of anti-phospholipids antibody [12]. Both in vivo and in vitro
studies showed that HIV has an ability to bind to the host cell
via their receptor found on the surface of the host cells. For
example, host cells that consist of the CD4 receptor, corecep-
tor chemokines ligand 4 (CXCR4), and chemokines receptor
5 (CCR5) interact with HIV, with the help of Glycoprotein
120 (gp120). This interaction reduces nitric oxide expression
that results in endothelial cell dysfunction and causes the im-
paired immune function of the vascular endothelial cell [13,
14].
Endothelial cells synthesize different molecules that are
involved in coagulation and fibrinolysis process. The compo-
nent produced by endothelial cells includes von Willebrand
factor (vWF), tissue plasminogen activator, plasminogen
activator inhibitor, and protein S [15]. InHIV-infected indivi-
duals, endothelial dysfunction is a common complication
caused by the effect of the virus and virus-associated im-
munological response. Such endothelial dysfunction acti-
vates the coagulation system, leading to the consumption
of coagulation factors [16]. Moreover, HIV infection causes
various abnormalities predisposing to a hypercoagulable state
including the presence of antiphospholipid antibodies and
lupus anticoagulant, deficiencies of protein C, protein S,
heparin cofactor II, and antithrombin and increased levels of
vWF and D-dimers [17, 18].
Persistent systematic inflammation, immune dysfunc-
tion, activation of lymphocyte and monocytes, and elevated
level of inflammatory cytokine are the hallmarks of HIV
infection, particularly in untreated and late stage of HIV
infections [1]. Thus, inflammation modulates thrombotic re-
sponse by upregulating procoagulants, downregulating anti-
coagulants, and suppressing fibrinolysis. The tissue damage,
by either viral-mediated or immune-mediated mechanisms,
releases cytokine and cellular products.These situations acti-
vate the endothelial surface to increase tissue factor expres-
sion, reduce endogenous anticoagulant signals, and promote
leukocyte infiltration [19, 20].
HIV-associated thrombocytopenia limits the hemostatic
role of platelet, particularly the primary hemostasis [21]. HIV
infection can also cause non-acquired immune deficiency
syndrome (AIDS) related complication including liver and
renal diseases. Such complications limit the production of
most coagulation factors, natural anticoagulants, fibrinolytic
factors, and hematopoietic growth hormones which may
contribute for hemostatic disorders [22, 23]. Furthermore,
highly active antiretroviral therapy (HAART) drugs have
adverse effects and cause hepatic damage that leads to a de-
creased production of coagulation factors [12]. HAARTdrugs
especially protease inhibitors cause endothelial dysfunction
by their effects on the metabolism of lipid and glucose [24].
Hence, the main aim of this study was to assess basic coagu-
lation parameters of HIV-infected in comparison with HIV-
seronegative individuals in Gondar, Northwest Ethiopia.
2. Materials and Methods
2.1. Study Design, Area, and Period. A comparative cross-
sectional study was conducted at the University of Gondar
Referral Hospital ART clinic from February to May 2017. The
University of Gondar Referral Hospital is found in Gondar
town, North Gondar zone, Amhara Regional State, Ethiopia.
The town is situated at an altitude of 2133meters above the sea
level. According to the 2007 Ethiopian census report, the pro-
jectile population of Gondar town in 2015 are 323,900 [25].
Currently, the town has one referral hospital and five govern-
ment health centres. The University of Gondar Referral Hos-
pital is a teaching hospital which servesmore than fivemillion
people in North Gondar zone and peoples of the neighbour-
ing zones.TheHIV care service of the hospital began in 2005,
and it has three adult ART clinics, one paediatric, one Volun-
tary Counselling and Testing (VCT) clinic, and 2 adherence
counselling clinics. Since 2005, when the hospital initiated
ART, 7581 adults and 738 paediatrics patients have been
enrolled. Currently, 5000 adults are actively being treated.
On average, around 400HIV-infected adults initiate HAART
annually.
2.2. Source and Study Population
2.2.1. Source Population. All HIV-infected adults who were
attending the University of Gondar Referral Hospital ART
clinic were taken as the source population for HIV-infected
adult groups. For the healthy control group, all adults who
were visiting VCT clinic were taken as the source population.
2.2.2. Study Population. HIV-infected adults who were
HAART-naı¨ve and taking HAART at the University of
Gondar Referral Hospital ART clinic during the study period
were included in the study for the case groups. For healthy
control, those serologically confirmed HIV-negative appar-
ently healthy adults who were visiting VCT clinic during the
study period were included in the study.
2.3. Inclusion and Exclusion Criteria
2.3.1. Inclusion Criteria. For HIV-infected groups, serologi-
cally confirmedHIV-infected adults whowereHAART-naı¨ve
BioMed Research International 3
and were taking HAART for at least one year were included
in the study. For the healthy control group, serologically
confirmed HIV-seronegative and apparently healthy adults
whowere volunteers to participate were included in the study.
2.3.2. Exclusion Criteria. Pregnant women, adults who were
on anticoagulant therapy, adults having a history of chronic
disease like hypertension, cardiac disease, and diabetes mel-
litus, and adults who were positive for hepatitis B surface
antigen test (HBsAg) and hepatitis C virus (HCV) were
excluded from the study for all groups.
2.4. Sample Size and Sampling Techniques. According to rules
of thumb that have been recommended by van Voorhis and
Morgan, 30 participants per group are required to detect real
differences, which could achieve an 80% power [26]. Thus,
a total of 300 study participants (100 HAART-naı¨ve HIV-
infected adults, 100HIV-infected adults who were taking
HAART, and 100HIV-seronegative apparently healthy age
and sex-matched control) were enrolled in the study. A sys-
tematic random sampling technique was used to select study
participants at the University of Gondar Referral Hospital
ART clinic and VCT clinic.
2.5. Data Collection Procedure. Sociodemographic charac-
teristics of study participant were collected using pretested
structured questionnaire. The questionnaire consists of two
parts. The first part of questionnaire consists of sociodemo-
graphic characteristics of study participants which include
age, sex, marital status, and residence. The second part of
questionnaire consists of questions regarding clinical infor-
mation of study participants, HAART usage, duration of
HAART, and WHO AIDS stage. Clinical information and
physical diagnosis of HIV-seronegative adults were assessed
by trained clinicians who were working at the University of
Gondar Referral Hospital VCT clinic.
2.6. Laboratory Analysis. Eight millilitres of venous blood
was collected: five millilitres in EDTA anticoagulated tube
for CD4 cell count, platelet count, and serological tests;
three millilitres in 3.2% sodium citrated anticoagulated tube
for basic coagulation parameters analysis. Platelet count
was determined using SYSMEX K-21N (Sysmex Corporation
Kobe, Japan), a three-part differential automated haemato-
logical analyzer. CD4 positive cell count was determined
using the FACS count automated analyzer (Becton Dicken-
son and Company, California, USA). For basic coagulation
parameters (PT, aPTT, and INR), platelet poor plasma was
prepared by centrifugation of sodium citrate anticoagulated
blood at 1500 g for 15 minutes. Then, PT and APTT were
determined using HUMACLOT DUE PLUS coagulation
analyzer (Wiesbaden, Germany). HBsAg and HCV antibody
were determined by colloidal gold enhanced immune-assay
(Xiamen Fujian, China, for HBsAg; Xiamen Fujian, China,
for HCV antibody). All laboratory tests were done following
standard operating procedure and themanufacturers’ recom-
mendation.
2.7. Data Quality Management. The questionnaire was pre-
pared in English, translated to local language-Amharic, and
then translated back to English to check the consistency.
Training was given for the data collectors about objective and
relevance of the study, confidentiality issues, study partici-
pants’ right, techniques of interview, and result recording.
Standard operating procedures and manufacturer instruc-
tionswere strictly followed throughout the procedures and all
reagents were stored and prepared according to the manufac-
turer’s instruction. The analytical quality of each laboratory
method was checked by running control materials before
analyzing the patients’ samples. The analysis of patients’
samples was done if and only if the methods passed the
quality control checking.
2.8. Statistical Analysis. Data were coded and entered into
Epi Info 7 statistical software and then exported to SPSS
version 20 for analysis. Homogeneity of variance was checked
using Levene’s statistics.TheKolmogorov-Smirnov normality
test was used for checking the distribution of continuous
variables, and it revealed that the variables were not normally
distributed for each group. Nonparametric tests, Kruskal-
Wallis H, and Dunn-Bonferroni pairwise comparison were
used for comparison of coagulation parameters between
groups. Spearman’s rank-order correlation analysis was used
to assess the correlation of CD4 count with basic coagulation
parameters and platelet count. The results were presented
as median [interquartile range] (IQR). Tables were used to
present the summarized data. In all statistical analysis, a 𝑃
value < 0.05 was considered as statistically significant.
2.9. Ethical Consideration. The studywas approved by School
of Biomedical and Laboratory Sciences, the University of
Gondar Research and Ethics Committee. Informed written
consent was taken from each of the study participants. All
the information obtained from the study participants was
kept confidential. Laboratory test results were communicated
to the responsible clinicians working at the University of
Gondar Referral Hospital ART clinic and VCT clinic.
3. Results
3.1. General Characteristics of Study Participants. A total of
300 adults who were attending the University of Gondar
Referral Hospital ART and VCT clinics from February to
May 2017 were included in the study. The study subjects
were categorized into three groups: apparently healthy HIV-
seronegative adults; HIV-infected adults taking HAART; and
HAART-naı¨ve HIV-infected adults. Each group consisted of
100 individuals. The median age of the study subjects was 35
years (IQR: 15 year). Of these enrolled individuals, 53.3% (𝑛 =
160) were females. From those 200HIV-infected adults, the
majority of them were classified as WHOHIV/AIDS clinical
stage I (Table 1).
3.2. Coagulation Profiles of Study Participants. As compared
to apparently healthy HIV-seronegative group, PT, APTT,
and INR were prolonged in HIV-infected adults who were
HAART-naı¨ve and taking HAART. For example, 10% appar-
ently health HIV-seronegative adults, 62% HIV-infected
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Table 1: Sociodemographic and clinical characteristics of study participants at University of Gondar Hospital ART clinic and VCT unit
(𝑛 = 300).
Variables
Study groups
Apparently healthy adults
(𝑛 = 100)
HIV-infected adults who were taking
HAART (𝑛 = 100) HAART-na¨ıve HIV infected adults (𝑛 = 100)
𝑛 (%) 𝑛 (%) 𝑛 (%)
Age (year)
18–24 39 (39) 3 (3) 7 (7)
25–34 34 (34) 21 (27) 35 (35)
35–44 16 (16) 41 (41) 31 (31)
45–54 8 (8) 27 (27) 16 (16)
>54 3 (3) 8 (8) 11 (11)
Sex
Male 58 (58) 35 (35) 45 (45)
Female 42 (42) 65 (65) 55 (55)
Residence
Urban 73 (73) 92 (92) 75 (75)
Rural 27 (27) 8 (8) 25 (25)
Religion
Orthodox 93 (93) 90 (90) 88 (88)
Protestant 1 (1) 0 2 (2)
Muslim 6 (6) 8 (8) 9 (9)
Other 0 2 (2) 1 (1)
Educational
status
Unable to read
and write 15 (15) 27 (27) 36 (36)
Primary school 24 (24) 16 (16) 27 (27)
Secondary
school 31 (31) 37 (37) 23 (23)
Tertiary school 30 (30) 20 (20) 14 (14)
Marital status
Single 67 (67) 10 (10) 30 (30)
Married 19 (19) 61 (61) 42 (42)
Divorced 11 (11) 8 (8) 18 (18)
Widowed 3 (3) 21 (21) 10 (10)
WHO stage
Stage I 91 (91) 77 (77)
Stage II 8 (8) 13 (13)
Stage III 0 6 (6)
Stage IV 1 (1) 4 (4)
adults who were taking HAART, and 87% of HIV-infected
adults who were HAART-naı¨ve had a prolonged PT value.
Thrombocytopenia was found in 8% of HIV-infected adults
who were taking HAART and 26% of HAART-naı¨ve HIV-
infected adults, but no thrombocytopenia was found in
apparently healthyHIV-seronegative control group (Table 2).
In the apparently healthy control group, the median
[IQR] values of PT, APTT, INR, platelet, and CD4 count
were 13.6 [2.6] seconds, 28.0 [5.18] seconds, 1.16 [0.24],
269.0 [85.7] × 103/𝜇l, and 629 [306] cells/𝜇l, respectively.
The median [IQR] values of PT, APTT, INR, platelet, and
CD4 count were 14.4 [2.57] seconds, 33.5 [10.22] seconds,
1.23 [0.25], 248 [83.0] × 103/𝜇l, and 383 [201] cells/𝜇l for
HIV-infected adults who were taking HAART, respectively
(Table 3).
3.3. Comparison of Basic Coagulation Parameters among
Study Groups. As the data were not normally distributed,
nonparametric tests (Kruskal-WallisH andDunn-Bonferroni
pairwise comparison test) were used to compare the median
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Table 2: Basic coagulation and platelet profiles of study participants.
Profile
HIV-seronegative adults
(𝑛 = 100)
HIV-infected adults taking
HAART (𝑛 = 100)
HAART-na¨ıve HIV-infected
adults (𝑛 = 100) Reference range
𝑛 (%) 𝑛 (%) 𝑛 (%)
PT
Normal 90 (90) 38 (38) 13 (13) 10–14 seconds
Prolonged 10 (10) 62 (62) 87 (87)
APPT
Normal 91 (91) 68 (68) 60 (60) 24–36 seconds
Prolonged 9 (9) 32 (32) 40 (40)
INR
Normal 90 (90) 44 (44) 15 (15) 0.8–1.2
Prolonged 10 (10) 56 (56) 85 (85)
Platelet count
Normal 100 (100) 92 (92) 74 (74) 150–400 × 103/ul
Low 0 8 (8) 26 (26)
HAART: highly active antiretroviral therapy; PT: prothrombin time; INR: international normalization ratio; APTT: activated partial thromboplastin time.
Table 3: Comparison of basic coagulation parameters, platelet count, and CD4 cells among groups (Kruskal-Wallis test andmultiple pairwise
comparison using Dunn-Bonferroni correction).
Parameters
HIV-seronegative adults
(𝑛 = 100)
HIV-infected adults taking
HAART (𝑛 = 100)
HAART-na¨ıve HIV-infected
adults (𝑛 = 100) 𝑃 value
Median [IQR] Median [IQR] Median [IQR]
PT (second) 13.6 [2.6] 14.4 [2.57] 15.8 [2.70] <0.001∗
APPT (Second) 28 [5.18] 33.5 [10.22] 35 [11.6] <0.001∗
INR 1.16 [0.24] 1.23 [0.25] 1.37 [0.28] <0.001∗
Platelet count (×103/𝜇l) 269 [85.7] 248 [83.0] 191 [104] <0.001∗
CD4 count (Cells/𝜇l) 629 [306] 383 [201] 258 [170] <0.001∗
Multiple pairwise comparisons using Dunn-Bonferroni correction
Parameters aVsb aVsc bVsc
PT (seconds) 0.011∗ <0.001∗ <0.001∗
APTT (seconds) <0.001∗ <0.001∗ 0.201
INR <0.022∗ <0.001∗ <0.001∗
Platelet count (×103/𝜇l) 0.032∗ <0.001∗ <0.001∗
CD4 count (Cells/𝜇l) <0.001∗ <0.001∗ <0.001∗
HAART: highly active antiretroviral therapy; PT: prothrombin time; INR: international normalization ratio; APTT: activated partial thromboplastin time; IQR:
interquartile range; aapparently healthy HIV-seronegative adults; bHIV-infected adults who were taking HAART; cHIV-infected adults who were HAART-
naı¨ve; ∗significant at 𝑃 < 0.05.
differences in basic coagulation parameters between study
groups. In Kruskal-Wallis analysis, the median [IQR] of PT,
APTT, and INR showed statistically significant difference
among the study groups (𝑃 < 0.001). In multiple pairwise
comparisons analysis using Dunn-Bonferroni pairwise com-
parison, the median [IQR] values of PT, APTT, and INR
of HIV-infected adults (both HAART and HAART-naı¨ve
groups) were significantly higher than the control group (𝑃 <
0.05). The median [IQR] values of PT and INR were signifi-
cantly prolonged in HAART-naı¨ve HIV-infected adults com-
pared to HIV-infected adults who were taking HAART
(𝑃 < 0.001). But the median [IQR] value of APTT did not
show significant differences between HAART-na¨ıve and
HAART groups (𝑃 = 0.201) (Table 3).
The platelet count was highest in apparently healthy
control subjects and lowest in HAART-naı¨ve HIV-infected
adults. In Kruskal-Wallis analysis, the result showed that
platelet count was significantly different among groups (𝑃 <
0.001). The median [IQR] of platelets was significantly lower
inHIV-infected adults (bothHAART-na¨ıve and on-HAART)
compared to apparently healthy control group (𝑃 < 0.05).
Moreover, in Dunn-Bonferroni pairwise comparison test, the
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median [IQR] platelet count of HAART-naı¨ve subjects was
significantly lower compared to HIV-infected adults taking
HAART (𝑃 < 0.001) (Table 3).
3.4. Correlation of CD4 Cell Count with Basic Coagulation
Parameters in HIV-Infected Adults. The correlation between
CD4 cell count and basic coagulation parameters (PT, APTT,
INR, and platelet count) among pre-HAART and on-HAART
HIV-infected adults is shown in Table 4. As indicated in
Table 4, Spearman’s rank-order correlation analysis showed
that CD4 count had been significantly and negatively corre-
lated with APTT in HAART-na¨ıve HIV-infected adults (rho
= −0.235; 𝑃 = 0.018) (Table 4).
3.5. Comparison of Basic Coagulation Parameters Based on
HAARTDuration. In Kruskal-Wallis comparison, there were
no statistically significant differences in the median [IQR]
of PT, APTT, INR, and platelet count between HIV-infected
adults taking HAART for <2 years, 2–5 years, and >5 years
(𝑃 > 0.05) (Table 5).
4. Discussion
In the present study, the overall coagulation abnormality
was higher in HIV-infected adults than HIV-seronegative
individuals. Prolonged PT,APTT, INR, and lowplatelet count
were found in HIV-infected adults. Different factors includ-
ing HIV-associated endothelial dysfunction, the presence of
anti-cardiolipin antibody, and liver disease were the possible
reason for the occurrence of coagulation system abnormality
in HIV patients [15, 27].
Our finding showed that platelet count was significantly
decreased in HIV-infected adults (both on-HAART and
HAART-naı¨ve) compared to those HIV-seronegative adults
(𝑃 value < 0.05). This study was in agreement with the re-
searches done in Karimnagar, India, and Mbarara, Uganda,
which found low platelet count in HIV patients compared
to HIV negatives [12, 13]. Studies conducted in Sudan, Benin
city of Nigeria, and the Anambra state of Nigeria also found
low platelet count in HIV-infected individuals compared to
healthy controls [28–30]. HIV infection reduces the platelets
count via immune-mediated destruction of platelet and
megakaryocytes, thrombotic thrombocytopenic purpura, im-
paired haematopoiesis [10, 31], and damaging of the liver [32].
However, in contrary to our study finding, a study conducted
in Cape Coast, Ghana, found that there was no statistically
significant difference in terms of platelet count betweenHIV-
infected patients and healthy controls [33]. The discrepancy
may be because of variation in population characteristics and
male to female ratio. In the Ghanaian study, the numbers
of female study participants in HIV-infected groups (75.5%)
were higher than those in HIV-seronegative groups (8%).
Evidence showed that the platelet count is higher in females
than males [34]. As a result of this, the statistically significant
difference in platelet count between the two groupsmight not
be observed in Ghanaian study.
This study revealed that the platelet count was signif-
icantly reduced in HAART-na¨ıve HIV-infected adults as
compared to HIV-infected adults who were taking HAART
(𝑃 < 0.001). Studies showed that HAART treatment reduces
viral load and increases CD4 count and production of
platelets [35]. The reduction of viral load and immune re-
storation in HIV-infected adults taking HAART may contri-
bute for high platelet count as compared to HAART-naı¨ve
adults. Moreover, reduction of viral load may decrease HIV-
associated hypercoagulative disorders [17].
In the present study, PT, APTT, and INR were signif-
icantly elevated in HIV-infected adults (both HAART and
HAART-naı¨ve) compared to HIV-seronegative adults (𝑃
value < 0.05). This finding was concordant with the studies
done in Jimma town of Ethiopia, Abia state city of Nigeria,
andBenin city ofNigeriawhich found significantly prolonged
PT, APTT, and INR in HIV-infected individuals compared to
controls [28, 36, 37]. Similarly, studies conducted in Owerri
and Anambra also found significantly high PT and APTT in
infected adults (𝑃 < 0.05) [7, 29]. HIV infection has been
associated with endothelial dysfunction, liver disease, and
factors predisposing for hypercoagulable state including the
presence of antiphospholipid antibodies and lupus anticoag-
ulant, and deficiencies of protein C and protein S which cause
activation and consumption of coagulation factors might be
the possible reason for the occurrence prolonged PT and
APTT in HIV-infected individuals [15, 27, 38–40]. However,
our finding was discordant with a study done in Sudan which
did not find a significant difference in PT and APTT between
HIV-infected individuals and healthy controls [41]. The pos-
sible reason for this variation may be due to differences in
coagulation analyzers, variation in comparison method, and
the use of minimum sample size in Sudanese study (only 40
study participants). But our study used relatively large sample
size; thus it improves the power of the statistical model to
show the real difference between the two groups.
The values of PT and INR value were significantly lower
inHIV-infected adults whowere takingHAART compared to
HAART-naı¨ve HIV-infected adults (𝑃 < 0.001). HAART has
been strongly associated with restoration of CD4 cell count
[35] and reduction of viral load, endothelial dysfunction,
and abnormal coagulation activation [42]. Consequently,
HAART may reduce the HIV-associated coagulation abnor-
malities, resulting in less prolongation of PT and INR. But
this finding was discordant with the study done in Anambra
state of Nigeria which finds no significant difference in PT
value between HIV-infected adults who were taking HAART
and HAART-naı¨ve groups. The variation may be explained
by the fact that a minimum of 6 months of HAART duration
was considered for inclusion of HAART groups in Anambra
study, whereas in our study a minimum of 1 year of HAART
duration was considered as inclusion criteria in HAART
group.
HAART treatment reduces the production of lupus
anticoagulant, and thus HIV-infected individuals who were
takingHAARThave lower lupus anticoagulant thanHAART-
naı¨ve subjects [43]. In this study, APTT value of HAART-
naı¨ve study subjects was higher than that of HAART groups,
though the difference was not statistically significant (𝑃 =
0.074). Even if the result was not statistically significant,
the high prevalence of lupus anticoagulant in HAART-na¨ıve
HIV-infected adults may be the possible reason for the
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Table 4: Spearman’s rank-order correlation (rho) of CD4 cell count with basic coagulation parameters and platelet count amongHIV-infected
adults.
Groups of study participants Variables Correlation coefficient Significance level
(rho)
HAART-na¨ıve group (𝑛 = 100)
PT −0.051 0.616
APTT −0.235 0.018∗
INR −0.078 0.438
Platelet count 0.073 0.469
HAART group (𝑛 = 100)
PT 0.11 0.276
APTT −0.116 0.355
INR 0.051 0.616
Platelet count 0.095 0.346
∗Significant at 𝑃 < 0.05; PT: prothrombin time; APTT: activated partial thromboplastin time; INR: international normalization ratio.
Table 5: Comparison of basic coagulation parameters and platelet count among HIV-infected adult taking HAART on the basis of HAART
duration (Kruskal-Wallis test).
Parameters
Duration of HAART (𝑛 = 100)
Significance value<2 years 2–5 years 5 years
Median [IQR] Median [IQR] Median [IQR]
PT 14.3 [3.15] 13.9 [2.05] 14.5 [2.75] 0.799
APTT 34.4 [7.30] 33.5 [11.95] 33.5 [12.08] 0.954
INR 1.22 [0.27] 1.18 [0.22] 1.24 [0.26] 0.778
Platelet count 253 [83.0] 253 [94.5] 238 [84.2] 0.774
HAART: highly active antiretroviral therapy; PT: prothrombin time; APTT: activated partial thromboplastin time; INR: international normalization ratio; IQR:
interquartile range.
occurrence of high APTT value in HAART-naı¨ve subjects.
Moreover, evidence suggested that HAART reduces the
activation of inflammatory markers and thus normalizes the
coagulation, though the concern that markers of endothelial
activation (vWF), coagulation (APTT), and inflammation
(fibrinogen) remained significantly elevated as compared to
HIH-seronegative adults [44].
In Spearman’s correlation test, the finding showed that
CD4 count of HIV-infected adults who were taking HAART
was not correlated with any coagulation parameters. But
in HAART-naı¨ve HIV-infected adults, the CD4 count was
significantly and inversely correlated with APTT.The finding
was in agreement with a study conducted in Nigeria, Iran,
and India [12, 45, 46]. The possible reason is that when CD4
count decreases there was an increase in the incidence of
lupus anticoagulant and anticardiolipin antibodies. Evidence
revealed that 53.5% of HIV-infected adults had circulating
anticoagulants [47]. Moreover, at the low CD4 count, HIV-
associated endothelial activation and liver damage are com-
mon complications [48]. Endothelial activation and liver
damage cause consumption of blood clotting factors and/or
abnormal production of liver-dependent clotting factors that
can result in the occurrence of prolonged APTT in HIV-
infected adults [7].
Our finding indicated that HAART duration did not sig-
nificantly differ between HIV-infected adults taking HAART
for <2 years, 2–5 years, and >5 years (𝑃 > 0.05). This is
in consonance with previous studies conducted in Anambra
state of Nigeria which reported no significant difference of
coagulation parameters among HAART experienced HIV-
infected patients with regard to HAART duration [29].
5. Limitation of the Study
In this study, only basic coagulation parameters such as PT,
APTT, INR, and platelet count were measured to assess coag-
ulation profile.The study did not include factor assay, so it has
a limitation in differentiating the exact cause of prolonged PT
and APTT. Besides, measurement of inflammatory markers
was no part of the study; this may influence the strength of
statistical differences between study groups.
6. Conclusion
Coagulation abnormality was higher in HIV-infected adults
than HIV-seronegative subjects. PT was significantly higher
in HAART-naı¨ve HIV-infected adults compared with an
HIV-infected adults takingHAART subjects, whereas platelet
count was significantly lower in HAART-naı¨ve group com-
pared to HAART group. In correlation analysis, only APTT
was inversely correlated with a CD4 cell count in HAART-
naı¨ve HIV-infected adults. In our study, comparison of coa-
gulation parameters between HAART-na¨ıve and HAART
groups indicated that HAART treatment has a positive im-
pact on coagulation profiles of HIV-infected adults. There-
fore, in addition to complete blood cell count, organ function
test, and CD4 cell count, coagulation tests like PT and APTT
8 BioMed Research International
need to be included in the routine tests for management of
HIV-infected patients. Moreover, multicentred prospective
studies by including the measurement of coagulation factors
and inflammatory markers need to be conducted.
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